Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 35 of 114

  1. DS1062-A-U304

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  2. DS6000-109

    Daiichi Sankyo

    Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer

    phase 3 small molecule active

    1 trial

  3. DS7300-188

    Daiichi Sankyo

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  4. DS7300-202

    Daiichi Sankyo

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule active

    1 trial

  5. DS8201-724

    Daiichi Sankyo

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  6. DS8201-772

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  7. DS8201-793

    Daiichi Sankyo

    Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. DS8201-854

    Daiichi Sankyo

    HER2-expressing endometrial cancer (IHC 3+/2+)

    phase 3 small molecule active

    1 trial

  9. DS8201-A-U302

    Daiichi Sankyo

    Metastatic breast cancer

    phase 3 small molecule active

    1 trial

  10. DS8201-A-U305

    Daiichi Sankyo

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  11. DS8201-A-U306

    Daiichi Sankyo

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  12. DSC/08/2357/32

    Italfarmaco S.p.A.

    JAK2V617F-positive high-risk Polycythemia Vera

    phase 3 small molecule active

    1 trial

  13. DSC/14/2357/50

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  14. DTG + 3TC

    ViiV Healthcare B.V.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  15. DTX301

    Ultragenyx UK Limited

    OTC Deficiency

    phase 3 gene therapy active

    1 trial

  16. DTX301-CL301

    Lacuna Pharma Pty Ltd

    Late-onset Ornithine transcarbamylase (OTC) deficiency

    phase 3 small molecule active

    1 trial

  17. DTX401

    Ultragenyx UK Limited

    Glycogen Storage Disease Type IA

    phase 3 gene therapy completed

    1 trial

  18. DTX401-CL301

    Lacuna Pharma Pty Ltd

    Glycogen Storage Disease Type Ia (GSDIa)

    phase 3 small molecule active

    1 trial

  19. DTaP-HB-PRP~T combined vaccine

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial

  20. DTaP-HB-PRP~T vaccine

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial

  21. DUO-O/D081RC00001

    AstraZeneca AB

    Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  22. DUO2025_01

    Lacuna Pharma Pty Ltd

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    phase 3 small molecule active

    1 trial

  23. DVS SR

    Wyeth is now a wholly owned subsidiary of Pfizer

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  24. DX-2930

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    3 trials

  25. DX-2930 - 300mg/2wk

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  26. DZ2024B0002

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  27. Dabrafenib

    Novartis Pharmaceuticals

    Malignant Melanoma

    phase 3 small molecule completed

    1 trial

  28. Daclatasvir

    Bristol-Myers Squibb

    Hepatitis C Virus Infection

    phase 3 small molecule completed

    2 trials

  29. Dactinomycin

    Children's Hospital of Fudan University

    Adult Kidney Wilms Tumor

    phase 3 mab active

    1 trial

  30. Danicopan

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  31. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  32. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    3 trials

  33. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction (HFpEF)

    phase 3 small molecule completed

    1 trial

  34. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction

    phase 3 small molecule completed

    1 trial

  35. Dapagliflozin

    AstraZeneca

    Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

    phase 3 small molecule completed

    1 trial

  36. Dapagliflozin 10 mg

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  37. Dapagliflozin 10 mg

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

    phase 3 small molecule completed

    1 trial

  38. Dara SC

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  39. Daratumumab

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    3 trials

  40. Darbepoetin alfa

    Amgen

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  41. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  42. Darovasertib

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    2 trials

  43. Darvadstrocel

    Takeda

    Complex Perianal Fistulas in Adult Participants With Crohn's Disease

    phase 3 mab completed

    1 trial

  44. Dasiglucagon 4 mg/ml

    Zealand Pharma A/S

    Children with congenital hyperinsulinism

    phase 3 small molecule active

    1 trial

  45. Dato-DXd

    AstraZeneca

    Breast Cancer

    phase 3 small molecule active

    2 trials

  46. Datopotamab deruxtecan for Stage I-III Triple-negative Bre…

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

  47. Datopotamab deruxtecan, DOCETAXEL

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  48. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.